The association of CD4 + T-cell counts and cardiovascular risk in treated HIV disease

AIDS

Volumn 26, Issue 9, 2012, Pages 1115-1120

  Ho, Jennifer E ^a   Scherzer, Rebecca ^b   Hecht, Frederick M ^b   Maka, Kristinalisa ^b   Selby, Van ^b   Martin, Jeffrey N ^b,c   Ganz, Peter ^b   Deeks, Steven G ^b   Hsue, Priscilla Y ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cardiovascular diseases; CD4 cell; HIV; risk factors; vasodilation

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTERY BLOOD FLOW; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE DURATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SMOKING; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; RNA, VIRAL; VIRAL LOAD;

EID: 84862794669     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328352ce54     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention (CDC). Epidemiology of HIV/AIDS-United States, 1981-2005. MMWR Morb Mortal Wkly Rep 2006; 55:589-592.
2. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4R counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007; 44:179-187.
3. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
4. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-1748.
5. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-1608.
6. Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, Craven DE, et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42:1325-1332.
7. Group DADS, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426.
8. Group DS, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
9. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
10. Ho JE, Deeks SG, Hecht FM, Xie Y, Schnell A, Martin JN, et al. Initiation of antiretroviral therapy at higher nadir CD4R T-cell counts is associated with reduced arterial stiffness in HIVinfected individuals. AIDS 2010; 24:1897-1905.
11. Ganz P, Vita JA. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 2003; 108:2049-2053.
12. Kelley CF, Barbour JD, Hecht FM. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 2007; 45:445-448.
13. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002; 16:1119-1129.
14. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257-265.
15. Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients 40 years of age with coronary artery disease. Am J Cardiol 1996; 78:1210-1214
16. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
17. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, 1967; Berkeley, California, USA. Berkeley, California: University of California Press, vol. 1; 1967. pp. 221-223.
18. Hoeting J, Madigan D, Raftery A, Volinsky C. Bayesian model averaging: a tutorial. Stat Sci 1999; 14:382-401.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
20. Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF Jr, et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004; 109:613-619.
21. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multiethnic study of atherosclerosis. Circulation 2009; 120:502-509.
22. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109:III27-III32.
23. Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, Craven DE, et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42:1325-1332.
24. Blum A, Hadas V, Burke M, Yust I, Kessler A. Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction. Clin Cardiol 2005; 28:149-153.
25. Charakida M, Donald AE, Green H, Storry C, Clapson M, Caslake M, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 2005; 112:103-109.
26. Blanco JJ, Garća IS, Cerezo JG, de Rivera JM, Anaya PM, Raya PG, et al. Endothelial function in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob Chemother 2006; 58:133-139.
27. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152 s. JAmCollCardiol 2008; 52:569-576.
28. Lichtenstein KA. HIV Outpatient Study Cohort (HOPS): low CD4 associated with new cardiovascular events [abstract]. In: International AIDS Conference on HIV Pathogenesis and Treatment, 2008; Mexico.
29. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4R count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848.
30. Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, et al. Low CD4RT-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22:1615-1624.
31. Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64-70.
32. Ehrenreich H, Rieckmann P, Sinowatz F, Weih KA, Arthur LO, Goebel FD, et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993; 150:4601-4609.
33. Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20:2275-2283.
34. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, LaneHC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.